Brain disorders touch more lives than almost any other area of medicine, yet they remain among the hardest to treat. Quantum BioPharma (NASDAQ: QNTM) is taking on that challenge with a diversified strategy that spans clinical drug development, consumer wellness and royalty-based partnerships.
The scale of the need is enormous. The World Health Organization reported that more than three billion people were living with a neurological condition in 2021. The overall burden of disability, illness and premature death from these conditions rose 18% since 1990.
Developing treatments for the brain is notoriously difficult. A Tufts Center for the Study of Drug Development analysis found that central nervous system drugs had a 6.2% clinical approval success rate. That was less than half the 13.3% rate for other drugs, and the successful CNS drugs also took longer to develop. Those odds make a single-product strategy risky. Companies that build several paths to value can keep advancing science even when one program faces delays. That thinking sits at the center of Quantum BioPharma’s approach.
The Toronto-based company notes that it is working “to develop novel solutions for brain and inflammatory disorders.” Its vision is to become a world-class, innovation-driven biopharmaceutical company that improves patients’ quality of life.
In practice, that mission spans three areas: Quantum focuses on neurodegenerative, metabolic and alcohol misuse disorders. Its strategy pairs pharmaceutical research with commercialization partnerships and licensing structures designed to support multiple potential revenue streams.
The company’s alcohol-related work shows how that model operates. Quantum invented unbuzzd, a supplement drink, and spun out the consumer version to Unbuzzd Wellness Inc. It retains a 19.48% stake and a 7% royalty on sales until payments reach $250 million, after which the rate falls to 3% in perpetuity.
That arrangement lets a partner handle consumer marketing while Quantum keeps its focus on science. The company also retained the rights to pharmaceutical and medical versions of the formula. It is developing one of them, REKVRY, for alcohol misuse treatment in emergency and hospital settings.
The pipeline extends into inflammation and pain as well. In 2025, Quantum’s Australian subsidiary received ethics approval for a phase 2 trial of FSD202. The drug contains ultra-micronized palmitoylethanolamide and is being studied for chronic pain in patients with mast cell activation syndrome. That trial was designed to enroll 60 patients in a randomized, double-blind, placebo-controlled study. Quantum’s two Australian subsidiaries oversee its clinical trial activities in the country.
The most advanced piece of the neurodegenerative strategy is Lucid-MS. This patented new chemical entity is designed to address demyelination, the breakdown of the protective coating around nerve fibers in multiple sclerosis. Unlike most MS drugs, it is not intended to directly suppress the immune system.
In preclinical models of multiple sclerosis, Lucid-MS stabilized the myelin sheath and promoted functional recovery of limb function, according to the company. In August, the FDA cleared Quantum’s IND application, allowing a phase 2 trial in progressive MS. “FDA clearance to proceed with our Lucid-MS Phase 2 trial is a transformative moment for Quantum and the result of years of dedicated scientific research,” said Quantum CEO Zeeshan Saeed.
Financial discipline is another part of the company’s strategy. In its second-quarter 2026 results, Quantum reported that total operating expenses fell 53% compared with the same quarter a year earlier. Combined cash, cash equivalents and digital assets reached about $9.5 million as of June 30, up from $4.1 million at the end of 2025. Management said that liquidity can fund planned operations to at least October 2027. “We brought total operating expenses down by more than 50% year-over-year in the second quarter,” observed CFO Donal Carroll.
While Lucid-MS may be Quantum Bio’s headline program, it sits within a broader plan. The company pairs clinical development with licensing, royalties and cost control. Together, those pieces give Quantum BioPharma several routes toward its goal of better treatments for brain and inflammatory disorders, and more ways to keep that work moving forward.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Disseminated on behalf of Adaptogenics Health Corp.and may include paid advertising. The federal government is…
University of Virginia researchers have developed an experimental method that uses ultrasound to deliver therapeutic…
Earth Science Tech’s ‘conglomerate’ business model has allowed it to leverage its internal tech stack,…
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. The movement toward…
Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as…
Immunotherapy is a relatively new approach in the treatment of cancer and it has had…